Myfortic (Mycophenolic Acid)

Mycophenolic acid blocks the enzyme inosine monophosphate dehydrogenase, which is essential for making guanine nucleotides. Lymphocytes rely on this pathway, so the drug selectively reduces their proliferation, dampening the immune reaction that could lead to organ rejection.

The dosage of Myfortic is individualized by the prescribing clinician based on the type of transplant, patient weight, kidney function, and other medications. Only a qualified healthcare professional should determine the appropriate dose.

Myfortic is generally not recommended for use during pregnancy or while breastfeeding because it may affect fetal development and pass into breast milk. Women of childbearing potential should discuss contraception and risk‑benefit considerations with their physician.

To request Myfortic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Myfortic (mycophenolic acid) is often used alongside calcineurin inhibitors such as tacrolimus or cyclosporine. Compared with azathioprine, it provides more potent lymphocyte suppression with a different side‑effect profile, making it a preferred option in many modern transplant protocols.

Myfortic should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and extreme heat to maintain its stability and potency.

Myfortic is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. The exact administration schedule—once or twice daily—depends on the individualized dosing plan.

Serious risks include severe infections, leukopenia or other blood‑cell deficiencies, and liver toxicity. Patients should be monitored regularly for signs of infection, abnormal blood counts, and liver enzyme changes, and report any concerning symptoms promptly.

Myfortic is contraindicated in individuals with known hypersensitivity to mycophenolic acid or any of its excipients, and in patients with active, uncontrolled infections. It should also be avoided in those receiving live vaccines or in whom immunosuppression is deemed unsafe.